IMMUNOASSAY FOR A NON-ENZYMATIC ARACHIDONATE DERIVATIVE

Information

  • Research Project
  • 3498768
  • ApplicationId
    3498768
  • Core Project Number
    R43GM047634
  • Full Project Number
    1R43GM047634-01A1
  • Serial Number
    47634
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/1993 - 31 years ago
  • Project End Date
    9/30/1993 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    4/1/1993 - 31 years ago
  • Budget End Date
    9/30/1993 - 31 years ago
  • Fiscal Year
    1993
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    11/24/1992 - 32 years ago

IMMUNOASSAY FOR A NON-ENZYMATIC ARACHIDONATE DERIVATIVE

A novel class of prostaglandin F2-like compounds formed in vitro or in vivo by a free-radical catalyzed noncyclooxygenase mechanism have recently been discovered. For normal humans, levels of these compounds (called F2-isoprostanes) range from 5-50 pg/mL plasma and 500-3000 pg/mg urinary creatinine, respectively. the in vivo concentration of F2- isoprostanes have been shown to increase dramatically in animal models of free-radical induced lipid peroxidation. Although the potential role(s) of isoprostanes in the pathophysiology of human diseases remain to be determined, preliminary evidence strongly suggests that measurement of isoprostane concentrations may have significant diagnostic potential for the assessment of oxidative stress and in specific disorders such as hepatorenal syndrome, rheumatoid arthritis, and carcinogenesis. Isoprostanes have thus far been detected by mass spectrometry. However, this is an expensive method that is not well suited for routine clinical determinations. In contrast, immunoassay is an established clinical procedure that is well suited for the detection of small amounts of specific fatty acid derivatives. The ultimate goal of the present proposal is the development of sensitive and specific immunoassays for isoprostanes that will facilitate (a) investigations of the physiologic and pathophysiologic roles of these compounds, and (b) clinical assessment of oxidative status.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    OXFORD BIOMEDICAL RESEARCH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    ROCHESTER HILLS
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    48309
  • Organization District
    UNITED STATES